Cases & Deals

  • Home
  • Practices
  • BioMarin obtains recommendation after judicial review

Share

BioMarin obtains recommendation after judicial review

December 2019

Client(s) BioMarin Pharmaceutical Inc.

Jones Day represented BioMarin Pharmaceutical Inc. in a judicial review application (as an interested party largely aligned with the claimants) in proceedings against The National Institute for Health and Care Excellence ("NICE"). This concerned NICE's decision to not recommend the drug Brineura for the treatment of Batten’s disease. This is an ultra-rare, fatal, genetic brain condition affecting an exceptionally small child population which, untreated, leads to death by the age of 12. The proceedings were settled with NICE exceptionally agreeing to reconsider its decision and recommending Brineura to be funded on the National Health Service. Cerliponase alfa is the first and only treatment for Battens proven to stabilise and slow the progression of the disease.

CO 1998/2019 and CO/2114/2019

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.